Following the publication of a second Call for Supply Offers on 8 April 2011, The AMC Secretariat is pleased to announce the signature of new supply agreements for Pneumococcal Vaccines under the Advance Market Commitment (AMC)
The following paragraphs are intended to provide specific information with regards to the starting date of supply, suppliers’ names, doses allocated, and amount of AMC funds that remain unallocated. The names of the participating companies are listed in alphabetical order.
On the week starting 12 December 2011, UNICEF as procurement agency on behalf of GAVI confirmed the entry into new supply agreements with GlaxoSmithKline (GSK) Biologicals and Pfizer Inc.
GSK will start supplying 18M doses annually (Annual Supply Commitment) from 2014 for a period of 10 years. The tail price for this agreement is US$3.50. Consequently 9% of the AMC funds are allocated to this manufacturer under this agreement according to the AMC terms and conditions. The total doses awarded to GSK under two supply agreements amounts to 48M annually.
Pfizer will start supplying 18M doses annually (Annual Supply Commitment) from 2014 for a period of 10 years. The tail price for this agreement is US$3.50. Consequently 9% of the AMC funds are allocated to this manufacturer under this agreement according to the AMC terms and conditions. The total doses awarded to Pfizer under two supply agreements amounts to 48M annually.
Capacity Development Period
In addition to those supply agreements, GSK and Pfizer Inc. have agreed to provide in total 9 million doses for each of the years 2012 and 2013 as part of the AMC capacity development period.
Shaping markets through providing incentives to manufacturers
UNICEF has opted not to award the full quantities of the GAVI Strategic Demand Forecast for 2016 in response to this second tender. In order to incentivize manufacturers to accelerate the development of new vaccines, to contribute to the creation of a healthy market with multiple suppliers, and to enhance the possibility to access lower tail prices through future offers, quantities have been reserved for award at a later point in time.
Status of allocation of PCV
52% of the AMC funds corresponding to US$780M remain unallocated and will be available for successive rounds of calls for offers.
Status on overall supply commitments
|Manufacturer||Date of signature||Annual supply commitment||Trial price||Supply start date||AMC Funds allocated|
|GSK||23 March 2010||30 million doses||US$ 3.50||January 2012||US$ 225 million|
|Pfizer Inc.||23 March 2010||30 million dose||US$ 3.50||January 2013||US$ 225 million|
|GSK||12 Dec 2011||18 million doses||US$ 3.50||January 2014||US$ 135 million|
|Pfizer Inc.||12 Dec 2011||18 million doses||US$ 3.50||January 2014||US$ 135 million|
Total contracted supply
|Year||2010||2011||2012||2013||2014 - 2020||2021||2022||2023|
|Doses contracted in 2010||7.2 million||24.2 million||50 million||60 million||60 million||28 million|| || |
|Doses contracted in 2011|| || ||9 million||9 million||36 million||36 million||36 million||18 million|